Mechanism of action

The literature describes thymosin alpha-1 as a pleiotropic immunomodulator acting primarily on cells of innate immunity. In murine models the peptide activates dendritic cells through Toll-like receptor signaling: a TLR9/MyD88-dependent cascade involving IRF7 and a TLR2-mediated component have been reported, with downstream increases in IL-12 production and Th1 polarization (Romani et al. 2004; Bozza et al. 2007). In parallel, thymosin alpha-1 induces indoleamine 2,3-dioxygenase (IDO) and thereby tryptophan catabolism in dendritic cells, establishing in these models a regulatory balance between inflammation and tolerance (Romani et al. 2006). Earlier work additionally describes promotion of T-cell precursor maturation, increased NK-cell activity and upregulated expression of MHC class I molecules (Garaci et al. 2007). These findings derive predominantly from cell culture and animal models; they describe signaling pathways, not proven therapeutic effects.

State of evidence

Thymosin alpha-1 has an extensive clinical development history. Hong Kong's current product register lists Zadaxin, containing thymalfasin, as HK-50907. This confirms the named medicine's product-specific registration, not authorization of other research products or efficacy in every studied indication. The mechanistic base derives from in-vitro work and mouse models of dendritic cells and TLR signaling. In sepsis, randomized controlled trials have produced conflicting results: the single-blind ETASS trial (361 patients) showed a statistically non-significant trend towards lower 28-day mortality (26.0 percent versus 35.0 percent; p = 0.062) and improvement of the immune marker mHLA-DR (Wu et al. 2013), whereas the double-blinded phase 3 TESTS trial (1106 patients) found no mortality benefit (hazard ratio 0.99; Wu et al. 2025). For many other investigated fields, such as oncology combination regimens, confirmatory phase 3 data are lacking. The TESTS trial did not significantly improve its primary 28-day mortality endpoint. Findings from other indications and a product registration cannot establish broad immunomodulatory efficacy or safety.

Questions about the research

What is thymosin alpha-1 investigated for in research?

Thymosin alpha-1 is investigated primarily as an immunomodulator: preclinically for activation of dendritic cells via Toll-like receptors and the balance of inflammation and tolerance, clinically as adjunct therapy in chronic hepatitis B and C, in sepsis, and as a vaccine adjuvant. There is additional research on oncology combination regimens and on age-related decline of immune function. The current Hong Kong register documents the specific thymalfasin product Zadaxin, registration HK-50907; this is not evidence of efficacy in every research setting.

What is the state of the evidence on thymosin alpha-1?

Clinical evidence is substantial but indication-specific and inconsistent. Hong Kong's current register lists the named Zadaxin medicine as HK-50907; this does not authorize other research products. In sepsis, the single-blind ETASS trial showed a statistically non-significant mortality trend, while the large double-blind phase 3 TESTS trial did not significantly improve its primary 28-day mortality endpoint. Registration and results from another indication cannot resolve these findings or establish broad efficacy and safety.

Sources

1. Romani et al., Blood 2004DOI: 10.1182/blood-2003-11-4036PMID: 14982877
2. Romani et al., Blood 2006DOI: 10.1182/blood-2006-02-004762PMID: 16741252
3. Bozza et al., Int Immunol 2007DOI: 10.1093/intimm/dxm097PMID: 17804687
4. Garaci et al., Ann N Y Acad Sci 2007DOI: 10.1196/annals.1415.044PMID: 17600290
5. Wu et al., Crit Care 2013DOI: 10.1186/cc11932PMID: 23327199
6. Wu et al., BMJ 2025DOI: 10.1136/bmj-2024-082583PMID: 39814420
7. Hong Kong Drug Office: Zadaxin for Injection 1.6 mg, HK-50907, product register updated September 25, 2026

Mechanism of action

The literature describes thymosin alpha-1 as a pleiotropic immunomodulator acting primarily on cells of innate immunity. In murine models the peptide activates dendritic cells through Toll-like receptor signaling: a TLR9/MyD88-dependent cascade involving IRF7 and a TLR2-mediated component have been reported, with downstream increases in IL-12 production and Th1 polarization (Romani et al. 2004; Bozza et al. 2007). In parallel, thymosin alpha-1 induces indoleamine 2,3-dioxygenase (IDO) and thereby tryptophan catabolism in dendritic cells, establishing in these models a regulatory balance between inflammation and tolerance (Romani et al. 2006). Earlier work additionally describes promotion of T-cell precursor maturation, increased NK-cell activity and upregulated expression of MHC class I molecules (Garaci et al. 2007). These findings derive predominantly from cell culture and animal models; they describe signaling pathways, not proven therapeutic effects.

State of evidence

Thymosin alpha-1 has an extensive clinical development history. Hong Kong's current product register lists Zadaxin, containing thymalfasin, as HK-50907. This confirms the named medicine's product-specific registration, not authorization of other research products or efficacy in every studied indication. The mechanistic base derives from in-vitro work and mouse models of dendritic cells and TLR signaling. In sepsis, randomized controlled trials have produced conflicting results: the single-blind ETASS trial (361 patients) showed a statistically non-significant trend towards lower 28-day mortality (26.0 percent versus 35.0 percent; p = 0.062) and improvement of the immune marker mHLA-DR (Wu et al. 2013), whereas the double-blinded phase 3 TESTS trial (1106 patients) found no mortality benefit (hazard ratio 0.99; Wu et al. 2025). For many other investigated fields, such as oncology combination regimens, confirmatory phase 3 data are lacking. The TESTS trial did not significantly improve its primary 28-day mortality endpoint. Findings from other indications and a product registration cannot establish broad immunomodulatory efficacy or safety.

Questions about the research

What is thymosin alpha-1 investigated for in research?

Thymosin alpha-1 is investigated primarily as an immunomodulator: preclinically for activation of dendritic cells via Toll-like receptors and the balance of inflammation and tolerance, clinically as adjunct therapy in chronic hepatitis B and C, in sepsis, and as a vaccine adjuvant. There is additional research on oncology combination regimens and on age-related decline of immune function. The current Hong Kong register documents the specific thymalfasin product Zadaxin, registration HK-50907; this is not evidence of efficacy in every research setting.

What is the state of the evidence on thymosin alpha-1?

Clinical evidence is substantial but indication-specific and inconsistent. Hong Kong's current register lists the named Zadaxin medicine as HK-50907; this does not authorize other research products. In sepsis, the single-blind ETASS trial showed a statistically non-significant mortality trend, while the large double-blind phase 3 TESTS trial did not significantly improve its primary 28-day mortality endpoint. Registration and results from another indication cannot resolve these findings or establish broad efficacy and safety.

Sources

1. Romani et al., Blood 2004DOI: 10.1182/blood-2003-11-4036PMID: 14982877
2. Romani et al., Blood 2006DOI: 10.1182/blood-2006-02-004762PMID: 16741252
3. Bozza et al., Int Immunol 2007DOI: 10.1093/intimm/dxm097PMID: 17804687
4. Garaci et al., Ann N Y Acad Sci 2007DOI: 10.1196/annals.1415.044PMID: 17600290
5. Wu et al., Crit Care 2013DOI: 10.1186/cc11932PMID: 23327199
6. Wu et al., BMJ 2025DOI: 10.1136/bmj-2024-082583PMID: 39814420
7. Hong Kong Drug Office: Zadaxin for Injection 1.6 mg, HK-50907, product register updated September 25, 2026